Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK... see more

TSX:FRX - Post Discussion

View:
Post by stockfy on Jan 28, 2021 5:09pm

Silent board

Why is this board so silent? Aren't any retail investors in FRX?
Comment by stockfy on Jan 28, 2021 5:10pm
Any idea when FRX will report the first revenue? Just a rough estimate. Thanks.
Comment by neuralProphet on Mar 01, 2021 12:44pm
Not too may shares outstanding + less than avg 100k shares trading in CanadaUS in total = not enough retail owners to light up a Stockhouse board. Yahoo forum has a bit more action. Revenue wise, need to wait for FRX to resubmit NDA first to clear up manufacturing concerns, then get regulatory approval.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities